Form 8-K - Current report:
SEC Accession No. 0001013762-25-001826
Filing Date
2025-03-25
Accepted
2025-03-25 06:45:44
Documents
14
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235496-8k_biomx.htm   iXBRL 8-K 23607
2 PRESS RELEASE DATED MARCH 25, 2025 ea023549601ex99-1_biomx.htm EX-99.1 66611
  Complete submission text file 0001013762-25-001826.txt   274370

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phge-20250325.xsd EX-101.SCH 3005
4 XBRL LABEL FILE phge-20250325_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE phge-20250325_pre.xml EX-101.PRE 22352
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0235496-8k_biomx_htm.xml XML 3647
Mailing Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003
Business Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003 972 723942377
BiomX Inc. (Filer) CIK: 0001739174 (see all company filings)

EIN.: 823364020 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38762 | Film No.: 25765737
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)